Cancer Research SABCS EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ying, H.
Right arrow Articles by Cheng, S.-Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ying, H.
Right arrow Articles by Cheng, S.-Y.
[Cancer Research 63, 5274-5280, September 1, 2003]
© 2003 American Association for Cancer Research

Regular Articles

Mutant Thyroid Hormone Receptor ß Represses the Expression and Transcriptional Activity of Peroxisome Proliferator-activated Receptor {gamma} during Thyroid Carcinogenesis

Hao Ying, Hideyo Suzuki, Li Zhao, Mark C. Willingham, Paul Meltzer and Sheue-Yann Cheng1

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892-4264 [H. Y., H. S., L. Z., S-Y. C.]; National Human Genome Research Institute, NIH, Bethesda, Maryland 20892-4264 [P. M.]; and Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1072 [M. C. W.]

The molecular genetics underlying thyroid carcinogenesis is not clear. Recent identification of a PAX8-peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) fusion gene in human thyroid follicular carcinoma suggests a tumor suppressor role of PPAR{gamma} in thyroid carcinogenesis. Mice harboring a knockin mutant thyroid hormone ß receptor (TRßPV) spontaneously develop thyroid follicular carcinoma through pathological progression of hyperplasia, capsular invasion, vascular invasion, anaplasia, and eventually, distant organ metastasis. This mutant mouse (TRßPV/PV mouse) provides an unusual opportunity to ascertain the role of PPAR{gamma} in thyroid carcinogenesis. Here, we show that the expression of PPAR{gamma} mRNA was repressed in the thyroid gland of mutant mice during carcinogenesis. In addition, TRßPV acted to abolish the ligand (troglitazone)-mediated transcriptional activity of PPAR{gamma}. These results indicate that repression of PPAR{gamma} expression and its transcriptional activity are associated with thyroid carcinogenesis and raise the possibility that PPAR{gamma} could be tested as a therapeutic target in thyroid follicular carcinoma.




This article has been cited by other articles:


Home page
 Mol. Cell. Biol.Home page
C. J. Guigon, L. Zhao, C. Lu, M. C. Willingham, and S.-y. Cheng
Regulation of {beta}-Catenin by a Novel Nongenomic Action of Thyroid Hormone {beta} Receptor
Mol. Cell. Biol., July 15, 2008; 28(14): 4598 - 4608.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
Y. Y Liu, H. Morreau, J. Kievit, J. A Romijn, N. Carrasco, and J. W Smit
Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma
Eur. J. Endocrinol., March 1, 2008; 158(3): 375 - 384.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
P. J. O'Shea, C. J. Guigon, G. R. Williams, and S.-y. Cheng
Regulation of Fibroblast Growth Factor Receptor-1 (Fgfr1) by Thyroid Hormone: Identification of a Thyroid Hormone Response Element in the Murine Fgfr1 Promoter
Endocrinology, December 1, 2007; 148(12): 5966 - 5976.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
F. Furuya, C. Lu, M. C. Willingham, and S.-y. Cheng
Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer
Carcinogenesis, December 1, 2007; 28(12): 2451 - 2458.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Y.-Y. Liu, R. S. Heymann, F. Moatamed, J. J. Schultz, D. Sobel, and G. A. Brent
A Mutant Thyroid Hormone Receptor {alpha} Antagonizes Peroxisome Proliferator-Activated Receptor {alpha} Signaling in Vivo and Impairs Fatty Acid Oxidation
Endocrinology, March 1, 2007; 148(3): 1206 - 1217.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. S. Kim, F. Furuya, H. Ying, Y. Kato, J. A. Hanover, and S.-y. Cheng
Gelsolin: A Novel Thyroid Hormone Receptor-{beta} Interacting Protein that Modulates Tumor Progression in a Mouse Model of Follicular Thyroid Cancer
Endocrinology, March 1, 2007; 148(3): 1306 - 1312.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
A. S. Rocha, R. Marques, I. Bento, R. Soares, J. Magalhaes, I. V. de Castro, and P. Soares
Thyroid hormone receptor {beta} mutations in the 'hot-spot region' are rare events in thyroid carcinomas
J. Endocrinol., January 1, 2007; 192(1): 83 - 86.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
F. Furuya, J. A. Hanover, and S.-y. Cheng
Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor
PNAS, February 7, 2006; 103(6): 1780 - 1785.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
O. Araki, H. Ying, F. Furuya, X. Zhu, and S.-y. Cheng
Thyroid hormone receptor {beta} mutants: Dominant negative regulators of peroxisome proliferator-activated receptor {gamma} action
PNAS, November 8, 2005; 102(45): 16251 - 16256.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
L. Lacroix, V. Lazar, S. Michiels, H. Ripoche, P. Dessen, M. Talbot, B. Caillou, J.-P. Levillain, M. Schlumberger, and J.-M. Bidart
Follicular Thyroid Tumors with the PAX8-PPAR{gamma}1 Rearrangement Display Characteristic Genetic Alterations
Am. J. Pathol., July 1, 2005; 167(1): 223 - 231.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. Kohrle
Guard Your Master: Thyroid Hormone Receptors Protect Their Gland of Origin from Thyroid Cancer
Endocrinology, October 1, 2004; 145(10): 4427 - 4429.
[Full Text] [PDF]

Home page
 EndocrinologyHome page
Y. Kato, H. Ying, M. C. Willingham, and S.-Y. Cheng
A Tumor Suppressor Role for Thyroid Hormone {beta} Receptor in a Mouse Model of Thyroid Carcinogenesis
Endocrinology, October 1, 2004; 145(10): 4430 - 4438.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
K. D. Burman
A New Paradigm in the Treatment of Carcinoma: Specific Molecular Targeting
Endocrinology, March 1, 2004; 145(3): 1027 - 1030.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
A. L. Lovering, J. P. Ride, C. M. Bunce, J. C. Desmond, S. M. Cummings, and S. A. White
Crystal Structures of Prostaglandin D2 11-Ketoreductase (AKR1C3) in Complex with the Nonsteroidal Anti-Inflammatory Drugs Flufenamic Acid and Indomethacin
Cancer Res., March 1, 2004; 64(5): 1802 - 1810.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.